Has Jennifer Domm received payments from drug or device companies?

Yes. Drug and device makers reported $359,445 in general payments to Jennifer Domm across 480 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jennifer Domm did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jennifer Domm come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jennifer Domm

Pediatric Hematology-Oncology · Nashville, TNNPI 1558395665

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $240,522 of the $359,445 with a category attached, or 66.9%. Novo Nordisk accounts for 89.2% of it on its own, with 59 other manufacturers making up the rest. 2025 is the largest year on record at $102,271, more than ten times the $7,507 reported in 2019. Among pediatric hematology-oncology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$359,445in general payments, 2019–2025

Across 480 payments — averaging $748.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$321K
Pfizer$17K
CSL Behring$8K
Takeda Pharmaceuticals U.S.A., Inc.$3K
Adaptive Biotechnologies Corporation$3K
Biomarin Pharmaceutical Inc.$2K
plus $6K from 54 others

$36,637in research payments, 2019–2025

Across 105 payments — averaging $348.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novo Nordisk AS$26K
Novartis$11K

What the payments were for

Consulting fees$45,10313%
Speaking & faculty fees$240,52267%
Travel & lodging$63,49818%
Food & beverage$10,2983%
Entertainment$240%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	278	$320,756
Pfizer	27	$16,713
CSL Behring	16	$8,400
Takeda Pharmaceuticals U.S.A., Inc.	8	$2,773
Adaptive Biotechnologies Corporation	7	$2,511
Biomarin Pharmaceutical Inc.	1	$1,900
Pharmacosmos Therapeutics Inc.	4	$1,638
BD	1	$400
Recordati_rare_diseases_inc.	1	$353
Tersera Therapeutics LLC	1	$313
Dr.reddy's Laboratories,inc.	1	$245
Novartis	6	$229
Sobi, Inc	8	$216
AstraZeneca	3	$209
Pharming Healthcare, Inc.	7	$164
Amgen	8	$142
Biogen	6	$134
Vertex	1	$124
Jazz Pharmaceuticals Inc.	4	$124
Springworks Therapeutics, Inc.	5	$123
Octapharma USA, Inc.	2	$114
Sanofi	4	$110
Agios Pharmaceuticals, Inc.	5	$108
UCB, Inc.	3	$101
Azurity Pharmaceuticals, Inc.	5	$97
USWM, LLC	3	$97
Insulet Corporation	6	$94
Syndax Pharmaceuticals, Inc.	3	$75
HEMA Biologics, LLC	4	$73
Endo Pharmaceuticals Inc.	4	$71
Krystal Biotech Inc	3	$68
Y-mabs Therapeutics, Inc.	3	$66
Mesoblast, Inc.	2	$62
Arbor Pharmaceuticals, Inc.	3	$53
Genentech USA, Inc.	2	$50
Aptevo Therapeutics Inc	2	$50
Catalyst Pharmaceuticals, Inc.	2	$49
Day One Biopharmaceuticals	2	$48
Sanofi-aventis U.S. LLC	2	$43
Kerecis Limited	1	$40
Medexus Pharma, Inc.	2	$40
Grifols USA, LLC	2	$35
Corium, LLC	1	$35
Ultragenyx Pharmaceutical Inc.	1	$32
Seagen Inc.	2	$31
Bayer	1	$30
Companion Medical, Inc.	2	$29
Ipsen Biopharmaceuticals, Inc	1	$28
Aquestive Therapeutics, Inc.	1	$26
Immedica Pharma US, Inc.	1	$22
SK Life Science, Inc.	1	$22
Amneal Pharmaceuticals LLC	1	$20
Livanova USA, Inc.	1	$19
Mirum Pharmaceuticals, Inc.	1	$18
Ferring Pharmaceuticals Inc.	1	$17
Johnson & Johnson	1	$16
Aucta Pharmaceuticals, Inc.	1	$16
AbbVie	1	$16
Phadia US Inc.	1	$16
Albireo Pharma, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NovoSeven$51,154
REBINYN$50,144
Esperoct$35,060
Alhemo$33,479
HYMPAVZI$9,464
HEMGENIX$7,879
NovoSeven RT$6,545
OXBRYTA$5,393
Idelvion$4,229
ICLUSIG$2,640
clonoSEQ$2,086
Roctavian$1,900
Monoferric$1,500
ULTOMIRIS$175
CASGEVY$124

How this compares

$359,445 in reported general payments places this provider in the 95th percentile of 113 pediatric hematology-oncology providers in Tennessee.

See all pediatric hematology-oncology providers in Tennessee →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	14	$200
Omeprazole	11	$195

Paid to pharmacies, not to this prescriber.

Other pediatric hematology-oncology in Nashville

Haydar FrangoulNashville$356K
Carrie KitkoNashville$51K
Michael DebaunNashville$39K
Alexandra BorstNashville$27K
James ConnellyNashville$21K
Scott BorinsteinNashville$21K
Clinton CarrollNashville$8K
Heather McDanielNashville$8K
Elizabeth YangNashville$7K
Meghann McManusNashville$4K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →